The purpose of the City of Hope Comprehensive Cancer Center is to reduce cancer incidence, morbidity and mortality by providing and organizational structure and administration that enhances the quality and interdisciplinary nature of competitively funded cancer research activities. The core grant provides for continuous planning and evaluation of research programs in light of new scientific opportunities and for broad technical support via state-of the-art shared facilities. The broad aims of the Cancer Center are to: 1) stimulate and facilitate collaborative research interactions among basic scientists, clinical researchers, and prevention and control investigators working in areas of potential relevance to cancer; 2) develop and support core research facilities to improve the effectiveness of the Center's research programs; and 3) support development of new investigators and programs needed to seize opportunities for advancing basic, translational and clinical cancer research progress. Over eighty percent of all clinical and research activities of the institution are devoted to the study and treatment of cancer, as well as the education of professionals and the public regarding cancer as a personal and public health issue. Fourteen program grants support center scientists and activities. Twenty new scientists were recruited to the Cancer Center with the resulting development or expansion of nationally recognized programs in bone marrow transplantation, genetic and molecular epidemiology, bioinformatics, immunotherapeutics, DNA repair, clinical cancer pharmacology and therapeutics, and gene therapy. Four new research programs in the Center join two preexisting programs in Hematologic Malignancies and Clinical and Experimental Therapeutics. New programs include two basic research programs (Genetic, Epigenetic and Post-Transcriptional Regulation, and DNA Damage and Repair); a clinical program (Cancer Immunotherapeutics); and a program in cancer prevention and control (Clinical, Genetic, and Psychosocial Determinants of Cancer Risk and Outcomes). There are three new core facilities: Functional Genomics, Transgenic Mice, and Biomedical Informatics.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Bzymek, Krzysztof P; Puckett, James W; Zer, Cindy et al. (2018) Mechanically interlocked functionalization of monoclonal antibodies. Nat Commun 9:1580
Nguyen, Huong Q; Ruel, Nora; Macias, Mayra et al. (2018) Translation and Evaluation of a Lung Cancer, Palliative Care Intervention for Community Practice. J Pain Symptom Manage 56:709-718
Mendez-Dorantes, Carlos; Bhargava, Ragini; Stark, Jeremy M (2018) Repeat-mediated deletions can be induced by a chromosomal break far from a repeat, but multiple pathways suppress such rearrangements. Genes Dev 32:524-536
Zhang, Jing; He, Zhiheng; Sen, Subha et al. (2018) TCF-1 Inhibits IL-17 Gene Expression To Restrain Th17 Immunity in a Stage-Specific Manner. J Immunol 200:3397-3406
Sun, Jie; He, Xin; Zhu, Yinghui et al. (2018) SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. Cell Stem Cell 23:355-369.e9
Satheesan, Sangeetha; Li, Haitang; Burnett, John C et al. (2018) HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy. J Virol 92:
Murad, John P; Kozlowska, Anna K; Lee, Hee Jun et al. (2018) Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Front Immunol 9:2268
Miao, Yifei; Ajami, Nassim E; Huang, Tse-Shun et al. (2018) Enhancer-associated long non-coding RNA LEENE regulates endothelial nitric oxide synthase and endothelial function. Nat Commun 9:292
Sen, Subha; Wang, Fei; Zhang, Jing et al. (2018) SRC1 promotes Th17 differentiation by overriding Foxp3 suppression to stimulate ROR?t activity in a PKC-?-dependent manner. Proc Natl Acad Sci U S A 115:E458-E467
Kanteti, Rajani; Mirzapoiazova, Tamara; Riehm, Jacob J et al. (2018) Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther 19:316-327

Showing the most recent 10 out of 1396 publications